Overview A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia Status: Completed Trial end date: 1969-12-31 Target enrollment: Participant gender: Summary To investigate the efficacy and safety of OPC-34712 in comparison with placebo in patients with schizophrenia. Phase: Phase 2/Phase 3 Details Lead Sponsor: Otsuka Pharmaceutical Co., Ltd.